Arcoxia (Etoricoxib) - COX-2 Selective Inhibitor - Drug Information
Drug information on the COX-2 selective inhibitor Arcoxia, generic name etoricoxib. Arcoxia is an investigational arthritis drug in development by Merck. On 04/27/2007, a non-approvable letter was issued for a FDA drug application filed for treating osteoarthritis symptoms. Merck will continue to market Arcoxia outside the United States. Arcoxia is currently sold in 63 countries.
What Are COX-2 Inhibitors?
A brief explanation and fast facts about the COX-2 inhibitors.
A brief explanation and fast facts about the COX-2 inhibitors.
04/27/2007: FDA Rejects Approval of Arcoxia
04/27/2007, According to Merck, the maker of Arcoxia, the FDA issued a non-approvable letter in response to a New Drug Application for treating osteoarthritis. To gain approval, the FDA indicated that Merck would need to provide additional data in support of the benefit-to-risk profile for Arcoxia.
04/27/2007, According to Merck, the maker of Arcoxia, the FDA issued a non-approvable letter in response to a New Drug Application for treating osteoarthritis. To gain approval, the FDA indicated that Merck would need to provide additional data in support of the benefit-to-risk profile for Arcoxia.
04/12/2007: Arcoxia Rejected By FDA Arthritis Advisory Committee
04/12/2007, Arcoxia (etoricoxib) was not recommended for approval today by the FDA Arthritis Advisory Committee. Arcoxia is sold in 63 countries, but is not approved in the United States. The FDA is not required to follow the recommendations of the Arthritis Advisory Committee but usually does.
04/12/2007, Arcoxia (etoricoxib) was not recommended for approval today by the FDA Arthritis Advisory Committee. Arcoxia is sold in 63 countries, but is not approved in the United States. The FDA is not required to follow the recommendations of the Arthritis Advisory Committee but usually does.
08/24/2006 Arcoxia History: Preliminary Analysis of MEDAL Data
08/24/2006, Long-awaited study analysis for Arcoxia (etoricoxib), a COX-2 inhibitor Merck & Co. hope will be the successor to Vioxx, has yielded both positive and negative results based on preliminary review. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-Term) Program consisted of three clinical trials - EDGE, EDGE II, and MEDAL.
08/24/2006, Long-awaited study analysis for Arcoxia (etoricoxib), a COX-2 inhibitor Merck & Co. hope will be the successor to Vioxx, has yielded both positive and negative results based on preliminary review. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-Term) Program consisted of three clinical trials - EDGE, EDGE II, and MEDAL.
The Newest Arthritis Medications
It is in your own best interest to know what new medication is coming next and learn about how it should work so you can discuss with your doctor whether you would be a candidate for the drug. But even though the newly marketed drugs and drugs still in development grab our attention, don't forget about older possibilities.
It is in your own best interest to know what new medication is coming next and learn about how it should work so you can discuss with your doctor whether you would be a candidate for the drug. But even though the newly marketed drugs and drugs still in development grab our attention, don't forget about older possibilities.
Arthritis Drugs: What Are My Options?
Medications have long been considered "traditional" treatment. Since individual response to a specific medication can vary and because possible side effects are also a factor, finding the most effective medication or combination of medications can be a more difficult process than one would expect.
Medications have long been considered "traditional" treatment. Since individual response to a specific medication can vary and because possible side effects are also a factor, finding the most effective medication or combination of medications can be a more difficult process than one would expect.
Inflammation: The Battle Within
Inflammation is a natural defense of the body to protect against foreign substances or injury, but it can cause problems in certain diseases.
Inflammation is a natural defense of the body to protect against foreign substances or injury, but it can cause problems in certain diseases.
Comparison: Celebrex And Vioxx
An overview of the similarities and differences between the new popular COX-2 inhibitors prescribed for the treatment of arthritis.
An overview of the similarities and differences between the new popular COX-2 inhibitors prescribed for the treatment of arthritis.
Reports Conflict On Safety Of COX-2
A report in the Journal of the American Medical Association conflicts with a report in Nature Medicine about the safety of new COX-2 inhibitors like Celebrex and Vioxx.
A report in the Journal of the American Medical Association conflicts with a report in Nature Medicine about the safety of new COX-2 inhibitors like Celebrex and Vioxx.
06/17/2005 Arcoxia History: Arcoxia Trials Will Continue
06/17/2005, Merck & Co. announced two phase III trials will continue. Results from the trials known as Medal and Edge II are expected to be submitted to the FDA in 2006.
06/17/2005, Merck & Co. announced two phase III trials will continue. Results from the trials known as Medal and Edge II are expected to be submitted to the FDA in 2006.
10/29/2004 Arcoxia History: Arcoxia Approval Delayed By FDA
10/29/2004, Merck has received an "approvable" letter from the U.S. Food and Drug Administration for Arcoxia. The FDA is requiring additional safety and efficacy data for Arcoxia before it will issue approval.
10/29/2004, Merck has received an "approvable" letter from the U.S. Food and Drug Administration for Arcoxia. The FDA is requiring additional safety and efficacy data for Arcoxia before it will issue approval.
01/09/2004 Arcoxia History: Etoricoxib Shows Comparable Efficacy
01/09/2004, Etoricoxib is as effective and well tolerated as is diclofenac at improving pain and function in patients with hip or knee osteoarthritis, according to a double-blind, active comparator-controlled, parallel-group study, from Doctor's Guide.
01/09/2004, Etoricoxib is as effective and well tolerated as is diclofenac at improving pain and function in patients with hip or knee osteoarthritis, according to a double-blind, active comparator-controlled, parallel-group study, from Doctor's Guide.
03/20/2003 Arcoxia History: Arcoxia Relieves Acute Gouty Arthritis
03/20/2003, Study results of patients with acute gouty arthritis demonstrated that Arcoxia (etoricoxib) 120 mg once daily relieved the pain of acute gouty arthritis as well as indomethacin (50 mg three times daily), a standard treatment for the disease, from Doctor's Guide.
03/20/2003, Study results of patients with acute gouty arthritis demonstrated that Arcoxia (etoricoxib) 120 mg once daily relieved the pain of acute gouty arthritis as well as indomethacin (50 mg three times daily), a standard treatment for the disease, from Doctor's Guide.
06/17/2002 Arcoxia History: Etoricoxib For Back Pain, RA, & Gout
06/17/2002, The investigational COX-2 inhibitor etoricoxib is showing promise with respect to providing relief in many painful conditions, including back pain, rheumatoid arthritis (RA), and acute gouty arthritis (AGA), from Doctor's Guide.
06/17/2002, The investigational COX-2 inhibitor etoricoxib is showing promise with respect to providing relief in many painful conditions, including back pain, rheumatoid arthritis (RA), and acute gouty arthritis (AGA), from Doctor's Guide.